Gilead’s Sofosbuvir Gets High Marks for HIV/HCV Co-Infection
Sofosbuvir appears safe and effective for HIV/HCV co-infected people
Produced in collaboration with hivandhepatitis.com
Published: 13 September 2012
HIV/HCV co-infected people taking the experimental hepatitis C virus polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV-negative patients, researchers reported on Wednesday at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. Side-effects were also similar and there was no sign of interactions with antiretroviral drugs in this 14-day study.
HIV-positive people with hepatitis C tend to experience more rapid liver disease progression than HIV-negative individuals and do not respond as well to interferon-based treatment. Adding new direct-acting anti-HCV drugs can improve response, but raises concerns about worsened side-effects and interactions with anti-HIV drugs. Furthermore, many co-infected people are considered ineligible for interferon-based therapy or cannot tolerate its side-effects, and await more effective interferon-free regimens.
Continue reading this entire article: